Xiaodong Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Xiaodong Yan has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Kelei Mao
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing, China
2 shared publications - Wei Wang
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Laboratory for Clinical Medicine, Capital Medical University, Beijing, China
2 shared publications Angyang Guo
School of Medical Humanities, Capital Medical University, Beijing, China
1 shared publicationFang Xin
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing, China
1 shared publication- Haixia Huang
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing, China
1 shared publication - Jiaqi Zhang
School of Basic Medical Sciences, Capital Medical University, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 15 June 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
NICD3 mediates pro-angiogenic effects through SMAD3/TGFBI axis in colorectal cancer
The consensus molecular subtype 4 (CMS4) of colorectal cancer (CRC) represents an aggressive, mesenchymal phenotype associated with the poorest clinical prognosis. Although angiogenesis is fundamental to CRC progression, current anti-VEGF therapies are frequently compromised by primary or acquired resistance, creating an urgent need to identify alternative vascular drivers. NOTCH3 is significantly enriched in CMS4 CRC, yet its direct role in modulating the tumor vasculature remains elusive. Here, integrating multi-center transcriptomic datasets with clinical validation, we identified NOTCH3 as a critical engine of CRC angiogenesis. In Stage IV clinical samples, NOTCH3 expression correlated significantly with microvessel density (MVD). Functionally, overexpression of the NOTCH3 intracellular domain (NICD3) dramatically enhanced endothelial tube formation and migration in vitro, while driving robust tumor vascularization in xenograft models. Through transcriptomic profiling, we identified the secreted factor transforming growth factor-beta-induced protein (TGFBI) as the essential downstream effector. Mechanistically, we demonstrate that NICD3 physically interacts with and upregulates SMAD3, thereby facilitating the direct transcriptional activation of TGFBI. Crucially, to translate these mechanistic insights, we utilized molecular docking and drug screening to identify the flavonoid Hesperidin (HES) as a potent binder of TGFBI. HES treatment effectively abolished NICD3-driven angiogenesis and suppressed tumor progression in vivo. Collectively, our findings characterize a novel NICD3/SMAD3/TGFBI signaling axis as a key vulnerability in CRC and propose HES as a promising precision therapeutic strategy for CRC patients with features of CMS4.
- 15 June 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessNICD3 mediates pro-angiogenic effects through SMAD3/TGFBI axis in colorectal cancer
The consensus molecular subtype 4 (CMS4) of colorectal cancer (CRC) represents an aggressive, mesenchymal phenotype associated with the poorest clinical prognosis. Although angiogenesis is fundamental to CRC progression, current anti-VEGF therapies are frequently compromised by primary or acquired resistance, creating an urgent need to identify alternative vascular drivers. NOTCH3 is significantly enriched in CMS4 CRC, yet its direct role in modulating the tumor vasculature remains elusive. Here, integrating multi-center transcriptomic datasets with clinical validation, we identified NOTCH3 as a critical engine of CRC angiogenesis. In Stage IV clinical samples, NOTCH3 expression correlated significantly with microvessel density (MVD). Functionally, overexpression of the NOTCH3 intracellular domain (NICD3) dramatically enhanced endothelial tube formation and migration in vitro, while driving robust tumor vascularization in xenograft models. Through transcriptomic profiling, we identified the secreted factor transforming growth factor-beta-induced protein (TGFBI) as the essential downstream effector. Mechanistically, we demonstrate that NICD3 physically interacts with and upregulates SMAD3, thereby facilitating the direct transcriptional activation of TGFBI. Crucially, to translate these mechanistic insights, we utilized molecular docking and drug screening to identify the flavonoid Hesperidin (HES) as a potent binder of TGFBI. HES treatment effectively abolished NICD3-driven angiogenesis and suppressed tumor progression in vivo. Collectively, our findings characterize a novel NICD3/SMAD3/TGFBI signaling axis as a key vulnerability in CRC and propose HES as a promising precision therapeutic strategy for CRC patients with features of CMS4.
- Open Access
- 25 July 2025
- Published by Elsevier in Neuroscience
- Vol. 583, 10-22
ASIC1-SOX8 axis in lower-grade glioma predicts good prognosis and is associated with inflammatory infiltration and subtype differentiation
- 25 July 2025
- Published by Elsevier in Neuroscience
- Vol. 583, 10-22
Open AccessASIC1-SOX8 axis in lower-grade glioma predicts good prognosis and is associated with inflammatory infiltration and subtype differentiation